Endothelin ETA receptor/lipid peroxides/COX-2/TGF-β1 signalling underlies aggravated nephrotoxicity caused by cyclosporine plus indomethacin in rats

British Journal of Pharmacology

Volumn 172, Issue 17, 2015, Pages 4291-4302

  Helmy, Maged W ^a   El Gowelli, Hanan M ^b   Ali, Rabab M ^b   El Mas, Mahmoud M ^b  

^a Damanhour University   (Egypt)

^b Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOOXYGENASE 2; CYCLOSPORIN; ENDOTHELIN A RECEPTOR; GLUTATHIONE; INDOMETACIN; LIPID PEROXIDE; MALONALDEHYDE; TRANSFORMING GROWTH FACTOR BETA1; UREA; PTGS2 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVITY; FIBROSING ALVEOLITIS; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULE DISORDER; LIPID PEROXIDATION; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TOXICITY TESTING; UPREGULATION; UREA BLOOD LEVEL; ACUTE KIDNEY FAILURE; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ACUTE KIDNEY INJURY; ANIMALS; CYCLOOXYGENASE 2; CYCLOSPORINE; INDOMETHACIN; LIPID PEROXIDES; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84938741902     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13199     Document Type: Article

References (63)

1. Abassi Z, Brodsky S, Gealekman O, Rubinstein I, Hoffman A, Winaver J, (2001). Intrarenal expression and distribution of cyclooxygenase isoforms in rats with experimental heart failure. Am J Physiol Renal Physiol 280: F43-F53.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
4. Altman RD, Perez GO, Sfakianakis GN, (1992). Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis. Am J Med 93: 396-402.
5. Amudha G, Josephine A, Sudhahar V, Varalakshmi P, (2007). Protective effect of lipoic acid on oxidative and peroxidative damage in cyclosporine A-induced renal toxicity. Int Immunopharmacol 7: 1442-1449.
6. Anjaneyulu M, Tirkey N, Chopra K, (2003). Attenuation of cyclosporine-induced renal dysfunction by catechin: possible antioxidant mechanism. Ren Fail 25: 691-707.
7. de Arriba G, Calvino M, Benito S, Parra T, (2013). Cyclosporine A-induced apoptosis in renal tubular cells is related to oxidative damage and mitochondrial fission. Toxicol Lett 218: 30-38.
8. Cauduro RL, Costa C, Lhulier F, Garcia RG, Cabral RD, Gonçalves LF, et al. (2005). Endothelin-1 plasma levels and hypertension in cyclosporine-treated renal transplant patients. Clin Transplant 19: 470-474.
9. Chatterjee PK, Cuzzocrea S, Brown PA, Zacharowski K, Stewart KN, Mota-Filipe H, et al. (2000). Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat. Kidney Int 58: 658-673.
10. Chen GF, Sun Z, (2006). Effects of chronic cold exposure on the endothelin system. J Appl Physiol 100: 1719-1726.
11. Compton SJ, Jones CG, (1985). Mechanism of dye response and interference in the Bradford protein assay. Anal Biochem 151: 369-374.
12. Dai Y, Palade P, Wang X, Mercanti F, Ding Z, Dai D, et al. (2014). High fat diet causes renal fibrosis in LDLr-null mice through MAPK-NF-κB pathway mediated by Ox-LDL. J Cardiovasc Pharmacol 63: 158-166.
13. Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A, (1987). Enhancement of cyclosporine A nephrotoxicity by diclofenac. Clin Nephrol 27: 213-214.
14. Drury RAB, Wallington EA, (1980). Carleton's Histological Techniques, 5th edn. Oxford University Press: New York.
15. Duru M, Nacar A, Yönden Z, Kuvandik G, Helvaci MR, Koç A, et al. (2008). Protective effects of N-acetylcysteine on cyclosporine-A-induced nephrotoxicity. Ren Fail 30: 453-459.
16. El-Mas MM, Afify EA, Omar AG, Mohy El-Din MM, Sharabi FM, (2003). Testosterone depletion contributes to cyclosporine-induced chronic impairment of acetylcholine renovascular relaxations. Eur J Pharmacol 468: 217-224.
17. El-Mas MM, Mohy El-Din MM, El-gowilly SM, Sharabi FM, (2004a). Regional and endothelial differences in the cyclosporine attenuation of adenosine receptor-mediated vasorelaxations. J Cardiovasc Pharmacol 43: 562-573.
18. El-Mas MM, Mohy El-Din MM, El-Gowilly SM, Sharabi FM, (2004b). Relative roles of endothelial relaxing factors in cyclosporine-induced impairment of cholinergic and beta-adrenergic renal vasodilations. Eur J Pharmacol 487: 149-158.
19. El-Mas MM, Zhang J, Abdel-Rahman AA, (2006). Upregulation of vascular inducible nitric oxide synthase mediates the hypotensive effect of ethanol in conscious female rats. J Appl Physiol 100: 1011-1018.
20. El-Mas MM, Sharabi FM, El-gowilly SM, Mohy El-Din MM, (2007). Inhibition of nitric oxide-guanylate cyclase-dependent and -independent signaling contributes to impairment of β-adrenergic vasorelaxations by cyclosporine. Biochem Pharmacol 73: 359-367.
21. El-Mas MM, El-Gowelli HM, Abd-Elrahman KS, Saad EI, Abdel-Galil AG, Abdel-Rahman AA, (2011). Pioglitazone abrogates cyclosporine-evoked hypertension via rectifying abnormalities in vascular endothelial function. Biochem Pharmacol 81: 526-533.
22. El-Mas MM, Mohy El-Din MM, Helmy MM, Omar AG, (2012). Redox imbalances incite the hypertensive, baroreflex, and autonomic effects of cyclosporine in rats. Eur J Pharmacol 694: 82-88.
23. El-Mas MM, Helmy MW, Ali RM, El-Gowelli HM, (2015). Celecoxib, but not indomethacin, ameliorates the hypertensive and perivascular fibrotic actions of cyclosporine in rats: role of endothelin signaling. Toxicol Appl Pharmacol 284: 1-7.
24. Gao X, Yang T, Liu M, Peleli M, Zollbrecht C, Weitzberg E, et al. (2015). NADPH oxidase in the renal microvasculature is a primary target for blood pressure-lowering effects by inorganic nitrate and nitrite. Hypertension 65: 161-170.
25. Gerloni V, Cimaz R, Gattinara M, Arnoldi C, Pontikaki I, Fantini F, (2001). Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology (Oxford) 40: 907-913.
26. Gökçe A, Oktar S, Yönden Z, Aydin M, Ilhan S, Ozkan OV, et al. (2009). Protective effect of caffeic acid phenethyl ester on cyclosporine A-induced nephrotoxicity in rats. Ren Fail 31: 843-847.
27. Hardy G, Stanke-Labesque F, Deveaux G, Devillier P, Sessa C, Bessard G, (2000). Cyclosporine A and cremophor EL induce contractions of human saphenous vein: involvement of thromboxane A2 receptor-dependent pathway. J Cardiovasc Pharmacol 36: 693-698.
28. Harris RC, Breyer MD, (2001). Physiological regulation of cyclooxygenase- 2 in the kidney. Am J Physiol Renal Physiol 281: F1-F11.
29. Helmy MM, El-Gowelli HM, (2012). Montelukast abrogates rhabdomyolysis-induced acute renal failure via rectifying detrimental changes in antioxidant profile and systemic cytokines and apoptotic factors production. Eur J Pharmacol 683: 294-300.
30. Henrion D, Laher I, (1993). Potentiation of norepinephrine-induced contractions by endothelin-1 in the rabbit aorta. Hypertension 22: 78-83.
31. Hink U, Münzel T, (2006). COX-2, another important player in the nitric oxide-endothelin cross-talk: good news for COX-2 inhibitors? Circ Res 98: 1344-1346.
32. Ishikawa A, Homma Y, (2012). Beneficial effect of ubiquinol, the reduced form of coenzyme Q10, on cyclosporine nephrotoxicity. Int Braz J Urol 38: 230-234.
33. Kaczmarek E, Gõrna A, Majewski P, (2004). Techniques of image analysis for quantitative immunohistochemistry. Rocz Akad Med Bialymst 49 (Suppl. 1): 155-158.
34. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
35. Koca O, Gökçe AM, Öztürk MI, Ercan F, Yurdakul N, Karaman MI, (2013). Effects of intensive cell phone (Philips Genic 900) use on the rat kidney tissue. Urol J 10: 886-891.
36. Leask A, (2009). Signaling in fibrosis: targeting the TGF beta, endothelin-1 and CCN2 axis in scleroderma. Front Biosci (Elite Ed) 1: 115-122.
37. Liu F, Mih JD, Shea BS, Kho AT, Sharif AS, Tager AM, et al. (2010). Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol 190: 693-706.
38. Lüscher TF, Barton M, (2000). Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102: 2434-2440.
39. Marklund S, Marklund G, (1974). Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47: 469-474.
40. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
41. Matsumura T, Suzuki T, Aizawa K, Sawaki D, Munemasa Y, Ishida J, et al. (2009). Regulation of transforming growth factor-beta-dependent cyclooxygenase-2 expression in fibroblasts. J Biol Chem 284: 35861-35871.
42. Mihara M, Uchiyama M, (1978). Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 86: 271-278.
43. Miller LW, (2002). Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2: 807-818.
44. Millette E, de Champlain J, Lamontagne D, (2003). Contribution of endogenous endothelin in the enhanced coronary constriction in DOCA-salt hypertensive rats. J Hypertens 21: 115-123.
45. Musson RE, Cobbaert CM, Smit NP, (2012). Molecular diagnostics of calcineurin-related pathologies. Clin Chem 58: 511-522.
46. Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H, (1995). Effect of a specific endothelin receptor A antagonist on mRNA level for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 44: 895-899.
47. Nasr MA, El-gowilly SM, El-Mas MM, (2010). Comparable renovascular protective effects of moxonidine and simvastatin in rats exposed to cigarette smoke. Vascul Pharmacol 53: 53-60.
48. Nasser SA, Elmallah AI, Sabra R, Khedr MM, El-Din MM, El-Mas MM, (2014). Blockade of endothelin ETA, but not thromboxane, receptors offsets the cyclosporine-evoked hypertension and interrelated baroreflex and vascular dysfunctions. Eur J Pharmacol 727: 52-59.
49. Neuhofer W, Pittrow D, (2009). Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence. Eur J Clin Invest 39 (Suppl. 2): 50-67.
50. Papachristou E, Papadimitropoulos A, Kotsantis P, Goumenos DS, Katsoris PG, Vlachojannis JG, (2009). Cyclosporine induces endothelin-1 mRNA synthesis and nitric oxide production in human proximal tubular epithelial cell cultures. Ren Fail 31: 372-376.
51. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
52. Perazella MA, Tray K, (2001). Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional non-steroidal anti-inflammatory drugs. Am J Med 111: 64-67.
53. Rajagopalan S, Laursen JB, Borthayre A, Kurz S, Keiser J, Haleen S, et al. (1997). Role for endothelin-1 in angiotensin II-mediated hypertension. Hypertension 30: 29-34.
54. Richardson RJ, Murphy SD, (1975). Effect of glutathione depletion on tissue deposition of methylmercury in rats. Toxicol Appl Pharmacol 31: 505-519.
55. Rosenberger C, Griethe W, Gruber G, Wiesener M, Frei U, Bachmann S, et al. (2003). Cellular responses to hypoxia after renal segmental infarction. Kidney Int 64: 874-886.
56. Singh M, Chaudhry P, Parent S, Asselin E, (2012). Ubiquitin-proteasomal degradation of COX-2 in TGF-β stimulated human endometrial cells is mediated through endoplasmic reticulum mannosidase I. Endocrinology 153: 426-437.
57. Tedesco D, Haragsim L, (2012). Cyclosporine: a review. J Transplant 2012: 230386.
58. Warner L, Yin M, Glaser KJ, Woollard JA, Carrascal CA, Korsmo MJ, et al. (2011). Noninvasive in vivo assessment of renal tissue elasticity during graded renal ischemia using MR elastography. Invest Radiol 46: 509-514.
59. Whiting PH, Barnard N, Neilsch A, Simpson JG, Burke MD, (1987). Interactions between cyclosporin A, indomethacin and 16,16-dimethyl prostaglandin E2: effects on renal, hepatic and gastrointestinal toxicity in the rat. Br J Exp Pathol 68: 777-786.
60. Williamson HE, (1988). Interaction of cyclosporine and indomethacin in the rat. Res Commun Chem Pathol Pharmacol 61: 141-144.
61. Wolf G, (2006). Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 70: 1914-1919.
62. Wong YF, Zhou H, Wang JR, Xie Y, Xu HX, Liu L, (2008). Anti-inflammatory and analgesic effects and molecular mechanisms of JCICM-6, a purified extract derived from an anti-arthritic Chinese herbal formula. Phytomedicine 15: 416-426.
63. Ybox drawings light down and leftlmaz N, Ilhan S, Nazbox drawings light down and leftroʇlu M, Oktar S, Nacar A, Arbox drawings light down and leftca V, et al. (2011). Ceftriaxone ameliorates cyclosporine A-induced oxidative nephrotoxicity in rat. Cell Biochem Funct 29: 102-107.